This study aims to compare multiple biomarkers (including AFP, the Doylestown algorithm, and aMAP score) in Chinese patients with cirrhosis and investigate the clinical utility of the Doylestown algorithm and aMAP score. The gene discussed is AFP; the disease is Cirrhosis.